Penguin Group (USA) Inc. v. American Buddha

L'Officiel USA successfully reached resolution with the City of New York, without admission of wrong-doing

Retrieved on: 
Thursday, August 10, 2023

This agreement reflects L'Officiel USA's commitment to support and restore fair compensation to certain freelancers employed by the Company's predecessor owners, without admission of wrongdoing, and marks the end of the City's claims that prior ownership had not fully compensated certain freelancers.

Key Points: 
  • This agreement reflects L'Officiel USA's commitment to support and restore fair compensation to certain freelancers employed by the Company's predecessor owners, without admission of wrongdoing, and marks the end of the City's claims that prior ownership had not fully compensated certain freelancers.
  • "We are steadfastly committed to the growth and success of L'Officiel USA.
  • Resolution of this matter reflects L'Officiel's overall commitment to a diverse and fair environment and its relationship with all its business partners, including the freelancers community.
  • Under the terms of the agreement with the City of New York, L'Officiel USA admits no wrongdoing and commits to notifying prior freelancers and compensating them for previously uncompensated work.

GITAI Conducts Successful Demonstration of Lunar Base Construction in a Mock Lunar Surface Environment

Retrieved on: 
Friday, March 24, 2023

TORRANCE, Calif., March 24, 2023 /PRNewswire/ -- GITAI USA Inc. (GITAI), the world's leading space robotics startup, conducted a successful demonstration of lunar base construction using two GITAI inchworm-type robotic arms and two GITAI Lunar Robotic Rovers in a simulated lunar environment.

Key Points: 
  • TORRANCE, Calif., March 24, 2023 /PRNewswire/ -- GITAI USA Inc. (GITAI), the world's leading space robotics startup, conducted a successful demonstration of lunar base construction using two GITAI inchworm-type robotic arms and two GITAI Lunar Robotic Rovers in a simulated lunar environment.
  • As the demand for lunar exploration and lunar base construction increases, there is a growing need for safe and affordable labor in space.
  • This ground demonstration test emulates tasks that will be required for future lunar explorations and lunar base constructions using four robots: two inchworm-type robotic arms and two lunar robotic rovers.
  • The following three sets of tests were conducted in the simulated lunar environment in the desert, and all tests were completed successfully:

EQS-News: CureVac Announces Pricing of Upsized Public Offering of Common Shares

Retrieved on: 
Monday, February 13, 2023

TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwritten public offering at a public offering price of $9.25 per share for gross proceeds of approximately $250 million.

Key Points: 
  • TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwritten public offering at a public offering price of $9.25 per share for gross proceeds of approximately $250 million.
  • CureVac has granted the underwriters a 30-day option to purchase up to an additional 4,054,054 common shares to be sold in the offering on the same terms and conditions.
  • All of the shares in the offering are to be sold by CureVac N.V.
  • Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC are acting as bookrunners for the offering.

EQS-News: CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

Retrieved on: 
Sunday, February 12, 2023

TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.

Key Points: 
  • TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.
  • Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC acted as bookrunners for the offering.
  • Van Lanschot Kempen (USA) Inc. acted as lead manager for the offering.
  • The offering was made pursuant to an effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (“SEC”) on September 17, 2021.

EQS-News: CureVac Announces Proposed Public Offering of Common Shares

Retrieved on: 
Sunday, February 12, 2023

TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.

Key Points: 
  • TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.
  • In addition, CureVac intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares to be sold in the offering on the same terms and conditions.
  • All of the shares in the offering are to be sold by CureVac N.V.
  • Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC are acting as bookrunners for the proposed offering.

GITAI Develops Inchworm-Type Robotic Arm Extending Both the Capability and Mobility of Space Robots and Completes Proof-of-Concept Demonstration (TRL 3)

Retrieved on: 
Tuesday, August 16, 2022

As the demand for development/construction tasks in space are increasing, the requirements for robots in space are becoming diverse and complex.

Key Points: 
  • As the demand for development/construction tasks in space are increasing, the requirements for robots in space are becoming diverse and complex.
  • GITAI has responded to these needs by developing the GITAI IN1, an inchworm-type robotic arm equipped with "grapple end-effectors" on both ends of the arm.
  • This ground demonstration test emulates tasks that will be required for future lunar explorations and lunar base constructions using two robots: GITAI IN1, an inchworm-type robotic arm, and GITAI R1, a lunar rover.
  • GITAI is developing highly capable, safe, and reliable robots to help build and maintain satellites, space stations, lunar bases, and even cities on Mars.

QYOU Media Reports $5.7 Million Revenue in Q4 2021

Retrieved on: 
Thursday, March 10, 2022

Original top end revenue guidance provided on May 31st 2021 for Q4 2021 had previously been disclosed as $4,500,000.

Key Points: 
  • Original top end revenue guidance provided on May 31st 2021 for Q4 2021 had previously been disclosed as $4,500,000.
  • Ltd and QYOU USA Inc. recorded the highest revenue and net cash positive Adjusted EBITDA results for the first time in company history.
  • QYOU Media CEO and Co-Founder, Curt Marvis commented, "We are thrilled to achieve our goal in Q4 2021 of building a solid financial foundation for growing our business and operating plan in 2022.
  • QYOU Media operates in India and the United States producing and distributing content created by social media stars and digital content creators.

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Hyzon Motors, Inc. (HYZN) Investors and Encourages Investors to Contact the Firm Before November 29, 2021

Retrieved on: 
Tuesday, October 26, 2021

Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • It focuses on developing medium and heavy-duty trucks, as well as city and coach buses.
  • On July 16, 2021, the merger between Decarbonization Plus Acquisition Corporation (Decarbonization) and Hyzon Motors USA Inc. f/k/a Hyzon Motors Inc. closed.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Hyzon Motors, Inc. (HYZN) Investors and Encourages Investors to Contact the Firm Before November 29, 2021

Retrieved on: 
Wednesday, October 20, 2021

Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Hyzon is a hydrogen mobility company that manufactures hydrogen-powered commercial vehicles and fuel cell systems.
  • On July 16, 2021, the merger between Decarbonization Plus Acquisition Corporation (Decarbonization) and Hyzon Motors USA Inc. f/k/a Hyzon Motors Inc. closed.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Hyzon Motors, Inc. (HYZN) Investors and Encourages Investors to Contact the Firm Before November 29, 2021

Retrieved on: 
Wednesday, October 13, 2021

Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • It focuses on developing medium and heavy-duty trucks, as well as city and coach buses.
  • On July 16, 2021, the merger between Decarbonization Plus Acquisition Corporation (Decarbonization) and Hyzon Motors USA Inc. f/k/a Hyzon Motors Inc. closed.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.